摘要
【摘 要】目的：探究将阿替普酶溶栓治疗方案应用于急性缺血性脑卒中患者治疗中的效果，评价其临床应用意义。方法：本次研究将时段 2017年 4月至 2019年 5月作为研究时段录入该时段内数据库中符合要求的 34例超早期急性脑梗死患者的个体资料进行统计分析，随机均分为对照组与实验组后，单组样本量设置为 17。对照组患者采用常规尿激酶治疗方案。实验组患者则在常规治疗的基础上，加用阿替普酶静脉溶栓治疗方案，对患者病程进行控制，评价两种治疗方案的应用效果。结果：本次研究成果显示，实验组患者治疗总有效率数据较对照组来说明显更高，即实验组患者治疗效果优于对照组，数据对比差异显著（ P<0.05）。结论：在对急性缺血性脑卒中患者进行治疗时，应用阿替普酶溶栓治疗方案能够有效促进治疗效果的提高，同时这种治疗方案不会对患者造成额外的用药并发症，具有较高的应用价值和用药安全性，值得推广使用。
【关键词】阿替普酶 ;急性缺血性脑卒中 ;临床效果
[Abstract] Objective: To explore the effect of thrombolytic therapy with ateplase in patients with acute ischemic stroke and evaluate its clinical significance. Methods: from April 2017 to may 2019, the data of 34 patients with super early acute cerebral infarction were recorded into the database for statistical analysis. After randomly divided into control group and experimental group, the sample size of single group was set to 17. The control group was treated with urokinase. On the basis of routine treatment, the patients in the experimental group were treated with intravenous thrombolysis with ateplase to control the course of the disease and evaluate the effect of the two treatment schemes. Results: the results of this study show that the total effective rate data of the experimental group is significantly higher than that of the control group, that is, the treatment effect of the experimental group is better than that of the control group, and the data comparison difference is significant (P < 0.05). Conclusion: in the treatment of acute ischemic stroke patients, the application of ateplase thrombolytic therapy can effectively promote the improvement of the treatment effect, at the same time, this treatment scheme will not cause additional drug complications for patients, with high application value and drug safety, it is worthy of promotion.
出版日期
2020年04月28日（中国期刊网平台首次上网日期，不代表论文的发表时间）
